PAM
LAB icon

Peak Asset Management’s Standard BioTools LAB Stock Holding History

Peak Asset Management’s Portfolio LAB Stock Details LAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-16,841
Closed -$45.6K – 149
2024
Q1 		$45.6K Buy
+16,841
New +$40.7K 0.01% 145

Other funds holding LAB

CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
TM
Tikvah Management Charlotte, North Carolina $329M AUM 64.12% 1-Year Est. Return

Peak Asset Management's LAB Position: Q2 2024 in Review

Peak Asset Management sold out of Standard BioTools (LAB) in Q2 2024, closing a stake of 16,841 shares — an estimated $45.6K sold.

Peak Asset Management first reported a position in LAB in Q1 2024 and held it in 1 quarter. The position peaked at $45.6K in Q1 2024. 145 funds tracked by Wall St. Rank hold LAB as of Q2 2024.

  • Peak Asset Management reported no remaining Standard BioTools position as of Q2 2024 after selling out during the quarter.
  • Peak Asset Management sold 16,841 Standard BioTools shares in Q2 2024, an estimated $45.6K.
  • Peak Asset Management first reported a position in Standard BioTools in Q1 2024 and held it in 1 quarter.
  • Peak Asset Management's Standard BioTools position peaked at $45.6K in Q1 2024.
  • 145 funds tracked by Wall St. Rank held Standard BioTools as of Q2 2024.

Based on Peak Asset Management's 13F filing for Q2 2024, filed 12 Aug 2024.